Multiple Myeloma (MM)

Oncology·MeSH: Multiple Myeloma

Prevalence

17.0 / 100K

Incidence

7.0 / 100K/yr

8 drugs in development·7 companies·6 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
clonoSEQ	Adaptive Biotechnologies Corp (ADPT)
lenalidomide	Mylan II B.V. (MYL)
thalomid	CELGENE CORP /DE/ (CELG)

Phase 2(2)

Drug	Company
cemsidomide	C4 Therapeutics, Inc. (CCCC)
nexi-002	NexImmune, Inc. (NEXI)

Phase 1(1)

Drug	Company
elranatamab	C4 Therapeutics, Inc. (CCCC)

Preclinical(2)

Drug	Company
al102	OLD AYALA, INC (AYLA)
sc255	Sana Biotechnology, Inc. (SANA)

BioSniper tracks 8 drugs in development for Multiple Myeloma (MM) across 7 companies.

There are 6 clinical trials targeting Multiple Myeloma (MM) tracked by BioSniper.

The estimated prevalence of Multiple Myeloma (MM) is approximately 17.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.